Oncology and Hematology News and Journal Articles
This article reviews the rationale for nanoparticle formulations of existing or previously investigated cytotoxic drugs, describe currently approved nanoparticle formulations of drugs, and discusses some of the most promising clinical trials currently underway.
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
A novel compound known as PM01183 showed promising activity in a two-stage phase II trial of women with platinum-resistant/refractory ovarian cancer.
In this interview we discuss the role of genetic testing in patients with colon cancer.
This video highlights recent research in cisplatin-resistant testicular cancer, including a study on whole exome sequencing that revealed several actionable targets.
Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.
The FDA has recently released a statement identifying a new rare T-cell lymphoma caused by breast implant surgery.
ASCO has released a statement announcing its opposition to President Trump’s budget outline for FY2018, which would cut about $6 billion in funding to the National Institutes of Health.
The journal ONCOLOGY includes a cartoon at the end of each issue. Here are the collected cartoons to date.